科研之友
微信
新浪微博
Facebook
分享链接
摘要
Rationale and Objectives: Health agencies making regulatory marketing-authorization decisions use qualitative and quantitative approaches to assess expected benefits and expected risks associated with medical interventions. There is, however, no universal standard approach that regulatory agencies consistently use to conduct benefit-risk assessment (BRA) for pharmaceuticals or medical devices, including for imaging technologies. Economics, health services research, and health outcomes research use quantitative approaches to elicit preferences of stakeholders; identify priorities, and model health conditions and health intervention effects. Materials and Methods: Challenges to BRA in medical devices are outlined, highlighting additional barriers in radiology. Three quantitative methods-multi-criteria decision analysis, health outcomes modeling and stated-choice survey-are assessed using criteria that are important in balancing benefits and risks of Medical devices and imaging technologies. Results: To be useful in regulatory BRA, quantitative methods need to: aggregate Multiple benefits and risks, incorporate qualitative considerations, account for uncertainty, and make clear whose preferences/priorities are being used. Each quantitative method performs differently across these criteria and little is known about how BRA estimates and conclusions vary by approach. While no specific quantitative Method is likely to be the strongest in all of the important areas, quantitative methods may have a place in BRA of medical devices and radiology. Discussion: Quantitative BRA approaches have been more widely applied in medicines, with fewer BRAs in devices. Despite substantial differences in characteristics of pharmaceuticals and devices, BRA methods may be as applicable to medical devices and imaging technologies as they are to pharmaceuticals: Further research to guide the development and selection of quantitative BRA Methods for medical devices and imaging technologies is needed.
- 出版日期2014-9
